Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor
出版年份 2016 全文链接
标题
Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor
作者
关键词
-
出版物
MEDICINAL RESEARCH REVIEWS
Volume 36, Issue 4, Pages 749-786
出版商
Wiley
发表日期
2016-05-03
DOI
10.1002/med.21392
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
- (2015) F. de Braud et al. ANNALS OF ONCOLOGY
- BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments
- (2015) Rodrigo F.E. Bogado et al. ANTI-CANCER DRUGS
- Activation of the endomitotic spindle assembly checkpoint and thrombocytopenia in Plk1-deficient mice
- (2015) M. Trakala et al. BLOOD
- A phase I study of volasertib combined with afatinib, in advanced solid tumors
- (2015) Jean-Pascal Machiels et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia
- (2015) Yukio Kobayashi et al. CANCER SCIENCE
- Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs
- (2015) M Hugle et al. CELL DEATH AND DIFFERENTIATION
- A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer
- (2015) Peter M. Ellis et al. Clinical Lung Cancer
- Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells
- (2015) Lilly Magdalena Weiß et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
- (2015) Ahmad Awada et al. INVESTIGATIONAL NEW DRUGS
- Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines
- (2015) Claudia Münch et al. LEUKEMIA RESEARCH
- Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
- (2015) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- Understanding the Polo Kinase machine
- (2015) V Archambault et al. ONCOGENE
- Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment
- (2015) Xiaoqi Liu Translational Oncology
- Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy
- (2015) Frank Louwen et al. Oncotarget
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- Polo-like kinase-1 in DNA damage response
- (2014) Sun-Yi Hyun et al. BMB Reports
- A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
- (2014) C-C Lin et al. BRITISH JOURNAL OF CANCER
- Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
- (2014) N. E. Bhola et al. CANCER RESEARCH
- Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
- (2014) Antonino Maria Spartà et al. CELL CYCLE
- Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery
- (2014) Klaus Strebhardt et al. Expert Opinion on Drug Discovery
- Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAFV600E Mutant Melanoma Cells
- (2014) Brian D. Cholewa et al. JOURNAL OF PROTEOME RESEARCH
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1
- (2014) Monika Raab et al. Molecular Oncology
- Polo-like kinases: structural variations lead to multiple functions
- (2014) Sihem Zitouni et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A novel role for Plk4 in regulating cell spreading and motility
- (2014) C O Rosario et al. ONCOGENE
- An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
- (2013) Walter M. Stadler et al. CANCER
- In vitro targeting of Polo-like kinase 1 in bladder carcinoma
- (2013) María Sol Brassesco et al. CANCER BIOLOGY & THERAPY
- Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma
- (2013) J A Pezuk et al. CANCER GENE THERAPY
- The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?
- (2013) B. D. Cholewa et al. CANCER RESEARCH
- Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53
- (2013) Mourad Sanhaji et al. CELL CYCLE
- Plk1: unexpected roles in DNA replication
- (2013) Ranadip Mandal et al. CELL RESEARCH
- Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors
- (2013) Michel D. Wissing et al. FASEB JOURNAL
- Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma
- (2013) Christian D. Fingas et al. HEPATOLOGY
- Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program
- (2013) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- A High-Content Small Molecule Screen Identifies Sensitivity of Glioblastoma Stem Cells to Inhibition of Polo-Like Kinase 1
- (2013) Davide Danovi et al. PLoS One
- Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation
- (2013) Mechthild Krause et al. RADIOTHERAPY AND ONCOLOGY
- Outlier Kinase Expression by RNA Sequencing as Targets for Precision Therapy
- (2013) Vishal Kothari et al. Cancer Discovery
- Abstract 2557: Preclinical synergy of Plk1 inhibitors and HDACIs
- (2012) Channing J. Paller et al. CANCER RESEARCH
- Abstract 2829: Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1
- (2012) Sean C. Semple et al. CANCER RESEARCH
- p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors
- (2012) Mourad Sanhaji et al. CELL CYCLE
- Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours
- (2012) A. Frost et al. Current Oncology
- The Structure of the Plk4 Cryptic Polo Box Reveals Two Tandem Polo Boxes Required for Centriole Duplication
- (2012) Lauren K. Slevin et al. STRUCTURE
- From Plk1 to Plk5
- (2011) Guillermo de Cárcer et al. CELL CYCLE
- PLK1 as an oncology target: current status and future potential
- (2011) Campbell McInnes et al. DRUG DISCOVERY TODAY
- A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
- (2011) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions
- (2011) El Mustapha Bahassi EXPERIMENTAL BIOLOGY AND MEDICINE
- Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies
- (2011) Daniel C Christoph et al. Expert Review of Anticancer Therapy
- Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer
- (2011) Zhao-Xia Wang et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression
- (2011) G. de Carcer et al. MOLECULAR AND CELLULAR BIOLOGY
- TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens
- (2011) Y. Hikichi et al. MOLECULAR CANCER THERAPEUTICS
- Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells
- (2010) Shilpa Tyagi et al. BIOCHEMICAL PHARMACOLOGY
- An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
- (2010) R.-D. Hofheinz et al. CLINICAL CANCER RESEARCH
- Future Prospect of RNA Interference for Cancer Therapies
- (2010) Eishi Ashihara et al. CURRENT DRUG TARGETS
- Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors
- (2010) Italo Beria et al. JOURNAL OF MEDICINAL CHEMISTRY
- Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
- (2010) Klaus Strebhardt NATURE REVIEWS DRUG DISCOVERY
- Plk4 is required for cytokinesis and maintenance of chromosomal stability
- (2010) C. O. Rosario et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis
- (2009) A. G. Gilmartin et al. CANCER RESEARCH
- A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis
- (2009) Wolfgang Reindl et al. CHEMBIOCHEM
- Identification and Validation of a Potent Type II Inhibitor of Inactive Polo-like Kinase 1
- (2009) Sarah Keppner et al. ChemMedChem
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
- The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation
- (2009) M. A. DiMaio et al. MOLECULAR CANCER THERAPEUTICS
- Polo-like kinases: conservation and divergence in their functions and regulation
- (2009) Vincent Archambault et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1
- (2009) Sang-Moon Yun et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions
- (2008) Wolfgang Reindl et al. CHEMISTRY & BIOLOGY
- Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1
- (2008) Mark Petronczki et al. DEVELOPMENTAL CELL
- Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma
- (2008) Yan-Bin Feng et al. INTERNATIONAL JOURNAL OF CANCER
- Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition
- (2008) Nobumoto Watanabe et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- RNA interference-mediated silencing of thepolo-like kinase 1gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells
- (2008) C. Yu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Polo-Like Kinase 1 Is Essential for Early Embryonic Development and Tumor Suppression
- (2008) L.-Y. Lu et al. MOLECULAR AND CELLULAR BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started